The future of medicine

Scroll to look closer

We find the targets that matter to treat cancer.

Each person is uniquely heterogenous and our technology was built for complexity.

A foundation model for personalized medicine, starting with cancer.

Trained on in-human data, Invoke’s model identifies what each person’s immune system can see so it can take action.

01

Trained on in-human data

A foundational model for personalized medicine, built from how real immune systems respond.

02

Reads each person’s immune system

Every immune system is different. The model learns from each one on its own terms.

03

Finds the targets that matter

The output is a short list of targets chosen for that one person, and nothing else.

The Invoke AI model reads one person's immune system and selects the targets for that person.

Grounded in published science.

Ideal targets for immunotherapy have to be visible to the immune system and expressed by a tumor. Invoke's AI maps the full tumor-immune system interaction to find the best targets for each individual.

CURRENT ALGORITHMS
Focus narrowly on the tumor target alone
INVOKE'S MODEL
Uses the entire immune system as the model
CANCER CELL
IMMUNE SYSTEM
TUMOR TARGET
PRESENTATION
MECHANISM

Experience from leading institutions in the field

Stanford Medicine
Genentech
MIT
Moderna
BioNTech
UC San Diego School of Medicine
Harvard Business School
Stanford Graduate School of Business
UC Berkeley
University of Pennsylvania
UC Santa Barbara
Wesleyan University

News and publications

Learning What Cancer Reveals: Introducing NEMo
bioRxiv Preprint
Publication
September 2026
Learning What Cancer Reveals: Introducing NEMo
Learning What Cancer Reveals: Introducing NEMo
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
QB3
News
June 2026
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
Invoke Bio Wins $100,000 QB3 Mentoring Program Award
New ML Tool Identifies Four Genetic Subtypes of Type 1 Diabetes, Enabling Earlier, Personalized Treatment
UC San Diego Today
News
April 2026
New ML Tool Identifies Four Genetic Subtypes of Type 1 Diabetes, Enabling Earlier, Personalized Treatment
New ML Tool Identifies Four Genetic Subtypes of Type 1 Diabetes, Enabling Earlier, Personalized Treatment
NeoPrecis Beats Tumor Mutation Burden as a Predictor of Immunotherapy Response
AACR 2026
Publication
April 2026
NeoPrecis Beats Tumor Mutation Burden as a Predictor of Immunotherapy Response
NeoPrecis Beats Tumor Mutation Burden as a Predictor of Immunotherapy Response
Invoke Bio's NEMo: Evolutionary Machine Learning for Neoantigen Immunogenicity Prediction
AACR 2026
Publication
April 2026
Invoke Bio's NEMo: Evolutionary Machine Learning for Neoantigen Immunogenicity Prediction
Invoke Bio's NEMo: Evolutionary Machine Learning for Neoantigen Immunogenicity Prediction
TJ Sears Named Co-Chair of US FNIH National Cancer Vaccines Initiative Subcommittee
Invoke Bio
News
April 2026
TJ Sears Named Co-Chair of US FNIH National Cancer Vaccines Initiative Subcommittee
TJ Sears Named Co-Chair of US FNIH National Cancer Vaccines Initiative Subcommittee
See all
news
Contact us

Patients and families: please don't include detailed medical information in your first message.

Message sent. A person on our team will reply.
Add your name, an email we can reply to, and a short message.